Transplantation

Environmental health

Population

Lymphoblastic Leukemia

Gastroenterology

Blinatumomab

Hematopoietic stem cell transplantation

Internal medicine

Leukemia

Minimal residual disease

Oncology

Immunology

Acute lymphocytic leukemia

Medicine

Blood

Among adults with MRD-positive ALL in hematologic remission after chemotherapy, 78% achieved a complete MRD response with blinatumomab. Complete MRD response after blinatumomab treatment in this population was associated with significantly improved OS.

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia